The controversy around anti-amyloid antibodies for treating Alzheimer’s disease

Abstract

The recent rejection of lecanemab by the European Medicines Agency despite its approval in other countries highlights the debate among researchers and regulatory bodies about the efficacy, safety, and underlying scientific basis of drugs to treat Alzheimer’s disease.